Literature DB >> 16224448

Reduction in central line-associated bloodstream infections among patients in intensive care units--Pennsylvania, April 2001-March 2005.

.   

Abstract

Each year, an estimated 250,000 cases of central line-associated (i.e., central venous catheter-associated) bloodstream infections (BSIs) occur in hospitals in the United States, with an estimated attributable mortality of 12%-25% for each infection. The marginal cost to the health-care system is approximately 25,000 dollars per episode. In 2001, CDC was invited by the Pittsburgh Regional Healthcare Initiative (PRHI) to provide technical assistance for a hospital-based intervention to prevent central line-associated BSIs among intensive care unit (ICU) patients in southwestern Pennsylvania. During a 4-year period, BSI rates among ICU patients declined 68%, from 4.31 to 1.36 per 1,000 central line days. The results suggest that a coordinated, multi-institutional infection-control initiative might be an effective approach to reducing health-care-associated infections.

Entities:  

Mesh:

Year:  2005        PMID: 16224448

Source DB:  PubMed          Journal:  MMWR Morb Mortal Wkly Rep        ISSN: 0149-2195            Impact factor:   17.586


  39 in total

1.  California hospitals response to state and federal policies related to health care-associated infections.

Authors:  Patricia W Stone; Monika Pogorzelska; Denise Graham; Haomiao Jia; Mayuko Uchida; Elaine L Larson
Journal:  Policy Polit Nurs Pract       Date:  2011-05

2.  Reduction of bloodstream infections associated with catheters in paediatric intensive care unit: stepwise approach.

Authors:  Adnan Bhutta; Craig Gilliam; Michele Honeycutt; Stephen Schexnayder; Jerril Green; Michele Moss; K J S Anand
Journal:  BMJ       Date:  2007-02-17

3.  Antimicrobial activity of omiganan pentahydrochloride against contemporary fungal pathogens responsible for catheter-associated infections.

Authors:  Thomas R Fritsche; Paul R Rhomberg; Helio S Sader; Ronald N Jones
Journal:  Antimicrob Agents Chemother       Date:  2008-01-07       Impact factor: 5.191

4.  CMS changes in reimbursement for HAIs: setting a research agenda.

Authors:  Patricia W Stone; Sherry A Glied; Peter D McNair; Nikolas Matthes; Bevin Cohen; Timothy F Landers; Elaine L Larson
Journal:  Med Care       Date:  2010-05       Impact factor: 2.983

5.  National estimates of central line-associated bloodstream infections in critical care patients.

Authors:  Matthew E Wise; R Douglas Scott; James M Baggs; Jonathan R Edwards; Katherine D Ellingson; Scott K Fridkin; L Clifford McDonald; John A Jernigan
Journal:  Infect Control Hosp Epidemiol       Date:  2013-04-18       Impact factor: 3.254

6.  Prevention of central line-associated bloodstream infections: a journey toward eliminating preventable harm.

Authors:  Kristina R Weeks; Christine A Goeschel; Sara E Cosgrove; Mark Romig; Sean M Berenholtz
Journal:  Curr Infect Dis Rep       Date:  2011-08       Impact factor: 3.725

7.  Effective state-based surveillance for multidrug-resistant organisms related to health care-associated infections.

Authors:  Jonathan Duffy; Dawn Sievert; Catherine Rebmann; Marion Kainer; Ruth Lynfield; Perry Smith; Scott Fridkin
Journal:  Public Health Rep       Date:  2011 Mar-Apr       Impact factor: 2.792

8.  A decade of investment in infection prevention: a cost-effectiveness analysis.

Authors:  Andrew W Dick; Eli N Perencevich; Monika Pogorzelska-Maziarz; Jack Zwanziger; Elaine L Larson; Patricia W Stone
Journal:  Am J Infect Control       Date:  2015-01       Impact factor: 2.918

Review 9.  State-mandated reporting of health care-associated infections in the United States: trends over time.

Authors:  Carolyn T A Herzig; Julie Reagan; Monika Pogorzelska-Maziarz; Divya Srinath; Patricia W Stone
Journal:  Am J Med Qual       Date:  2014-06-20       Impact factor: 1.852

10.  Cost-effectiveness of a central venous catheter care bundle.

Authors:  Kate A Halton; David Cook; David L Paterson; Nasia Safdar; Nicholas Graves
Journal:  PLoS One       Date:  2010-09-17       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.